StockData
BioAge Labs, Inc. logo

BioAge Labs, Inc. (BIOA) stock

BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$5.10−0.12 (-2.30%)

Close on Nov 17, 2026Market cap $234.07MP/E –Yield –

BioAge Labs r&d expenses

Research and development expenses are spending on new products and technology.

BioAge Labs's R&D Expenses for the twelve months ending Jun 30, 2026 was $87.79M, up 25.1% year over year. For fiscal 2025 it was $73.97M, up 25.3% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$73.97M+25.3%
FY2024Dec 31, 2024$59.04M+74.2%
FY2023Dec 31, 2023$33.89M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$24.37M+22.8%
Q1 FY2026Mar 31, 2026$20.41M+83.7%
Q4 FY2025Dec 31, 2025$24.50M+27.4%
Q3 FY2025Sep 30, 2025$18.51M-7.5%
Q2 FY2025Jun 30, 2025$19.84M+89.5%
Q1 FY2025Mar 31, 2025$11.11M+19.2%
Q4 FY2024Dec 31, 2024$19.23M+90.7%
Q3 FY2024Sep 30, 2024$20.02M+206.5%
Q2 FY2024Jun 30, 2024$10.47M–
Q1 FY2024Mar 31, 2024$9.32M–
Q4 FY2023Dec 31, 2023$10.08M–
Q3 FY2023Sep 30, 2023$6.53M–

More BioAge Labs figures

See a number that looks wrong?